Clues to COVID-19's vulnerability emerge from an antibody
An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the new coronavirus at the root of COVID-19, according to a study from scientists at Scripps Research.
The study, published today in Science, is the first to map a human antibody's interaction with the new coronavirus at near-atomic-scale resolution. Although the antibody was produced in response to an infection of SARS (severe acute respiratory syndrome), which is caused by the SARS-CoV virus, it cross-reacts with the new coronavirus, SARS-CoV-2.
The structural mapping revealed a nearly identical site on both coronaviruses to which the antibody binds, suggesting a functionally important and vulnerable site for this family of coronaviruses.
"The knowledge of conserved sites like this can aid in structure-based design of vaccines and therapeutics against SARS-CoV-2, and these would also protect against other coronaviruses--including those that may emerge in the future," says the study's senior author Ian Wilson, DPhil, Hansen Professor of Structural Biology and Chair of the Department of Integrative Structural and Computational Biology at Scripps Research.
2026-10-14
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
As Low as $25/session! Pfizer's COVID-19 Oral Drug Paxlovid Generic Drug Price Released
-
Survey On Corona Deaths By Country
-
COVID-19 Drug Remdesivir Approved for Infants And Young Children
-
Roche's Q1 Performance Increases by 10%, And Total Revenue for the Year May Slow Down Due to COVID-19, Biosimilar Competition
Recommend Reading
-
When the Skin of Ships Gets More Expensive: A 30% Price Shock Is Quietly Rewriting the Cost Floor of Global Shipping
-
Wanhua Chemical’s 2025 Revenue Exceeds RMB 200 Billion While Net Profit Remains Under Pressure
-
ARLANXEO Launches State-of-the-Art HNBR Plant in Changzhou, Strengthening Asia-Pacific Supply
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
This Week, China's Acetone Market Hits Bottom and Rebounds Slightly
-
Ethylene Glycol Prices Stabilize After Falling, Market Expected to Bottom Out and Recover
-
Weak Demand Leads to Narrow Fluctuations in the Melamine Market in China
-
Business Society’s PTA Trend Analysis for September 17, 2026: Volatility
-
Soda Ash Market Remains Stable Amidst Caution